Altimmune
ALT
126 hedge funds and large institutions have $767M invested in Altimmune in 2022 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 37 increasing their positions, 35 reducing their positions, and 30 closing their positions.
719% more call options, than puts
Call options by funds: $60M | Put options by funds: $7.33M
30% more capital invested
Capital invested by funds: $588M → $767M (+$179M)
17% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 30
3% more funds holding
Funds holding: 122 → 126 (+4)
6% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 35
0.96% more ownership
Funds ownership: 93.92% → 94.88% (+0.96%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$28.3M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$14.7M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$12.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.6M |
| 5 |
Jennison Associates
New York
|
+$8.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$15.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$12.5M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.64M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.58M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.47M |
ALT Hedge Fund Activity: Q4 2022 in Review
126 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q4 2022, worth a combined $767M — up 30% from $588M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ALT positions and 30 closed out — a net gain of 5 holders — while 37 added to existing stakes and 35 trimmed.
The largest buyer was State Street, adding an estimated $28.3M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $15.6M sold.
- 126 institutional investors held Altimmune (ALT) as of Q4 2022, up from 122 in Q3 2022.
- Funds reported $767M of Altimmune stock for Q4 2022, up 30% quarter-over-quarter.
- 35 funds opened new Altimmune positions in Q4 2022 and 30 closed out, a net change of +5 holders.
- The largest Altimmune buyer in Q4 2022 was State Street, an estimated $28.3M added.
- The largest Altimmune seller in Q4 2022 was Driehaus Capital Management, an estimated $15.6M sold.
Based on aggregated 13F filings for Q4 2022.